US Stock MarketDetailed Quotes

AVXL Anavex Life Sciences

Watchlist
  • 12.350
  • +0.200+1.65%
Close Jan 3 16:00 ET
  • 12.300
  • -0.050-0.40%
Post 20:01 ET
1.05BMarket Cap-23.75P/E (TTM)

Anavex Life Sciences Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Anavex Life Sciences Q4 2024 Earnings Date

Currency：USDDec 23, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
EPS
-0.16
-0.14
+0.02
Beat Est.
-36.11%
-7.69%
+14.22%
Net Income
--
-11.62M
--
-14.53%
Analyst Rating
Buy

Dec 31, 2024

Anavex Life Sciences Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 0.000--
--2025/Q1-- / 0.000--
Dec 23, 20242024/Q40.000 / 0.000--
Aug 6, 20242024/Q30.000 / 0.000--
May 9, 20242024/Q20.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 0.000--
--2025/Q1-- / 0.000--
Dec 23, 20242024/Q40.000 / 0.000--
Aug 6, 20242024/Q30.000 / 0.000--
May 9, 20242024/Q20.000 / 0.000--

Unlock Free Earnings Estimates

Anavex Life Sciences Earnings Reports

  • Anavex Life Sciences | 10-K: FY2024 Annual Report

    Dec 23, 2024 16:33 ET

  • Anavex Life Sciences | 10-Q: Q3 2024 Earnings Report

    Aug 6, 2024 17:24 ET

  • Anavex Life Sciences | 10-Q: Q2 2024 Earnings Report

    May 9, 2024 16:39 ET

  • Anavex Life Sciences | 8-K: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

    May 9, 2024 08:02 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DexCom
    DXCM
    +3.27%
    Collegium Pharmaceutical
    COLL
    +3.07%
    Lantheus
    LNTH
    +2.71%
    Cars.com
    CARS
    +1.72%
    YETI Holdings
    YETI
    +1.60%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 31, 2024

    Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data